LL-37 research, identity and evidence limits
LL-37 is a human host-defense peptide investigated in wound healing. Topical clinical findings are mixed and cannot establish the benefits of systemic administration.
Identity and formulation
The named molecule is a 37-residue cathelicidin-derived peptide. A fragment, modified analogue or combination with another antimicrobial needs a separate identity and evidence record.
The human trials reviewed here used topical formulations on particular wound types alongside clinical care. They did not test a general injectable immune booster.
What the studies show
A larger venous-ulcer trial failed to show an overall healing advantage, while a smaller diabetic-foot-ulcer study reported a granulation measure improving. These results should be presented together. Different wounds, preparations and endpoints can produce different findings without demonstrating a universal wound-healing effect.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Phase-IIb randomized double-blind topical trial in 148 patients, with compression treatment Reading scope: PubMed abstract |
The study did not show significant improvement in healing for the overall population. A post hoc larger-ulcer subgroup appeared to benefit. | An exploratory subgroup after an overall negative result needs confirmation in a trial designed for that population. |
| Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial
Four-week randomized topical-cream study in mildly infected diabetic foot ulcers Reading scope: PubMed abstract |
The granulation index improved, but measured inflammatory cytokines and aerobic bacterial colonization did not significantly decrease. | A tissue-healing measure is not evidence of eradicated infection, complete closure or effectiveness by another route. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Complete wound closure, speed of closure, granulation and bacterial burden are not interchangeable outcomes. A description should state which one improved and which did not.
A post hoc subgroup can generate a useful research question, but emphasizing it while omitting the overall null result would give readers a distorted impression.
Clinical wound care was part of the setting. These papers do not establish replacement of compression, assessment of circulation or infection management.
Safety context
The topical studies cannot characterize systemic exposure, interactions or uncommon harms from another formulation. Being a naturally occurring human peptide does not establish the safety of supplemental administration.
Study exposure and units
Read topical concentration together with the amount applied, wound area, treatment duration and background care. A concentration in a cream is not a systemic dose.
Keep endpoints at their reported follow-up. A four-week granulation result cannot become a claim of permanent healing or reduced amputation risk without those outcomes being studied.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Check that the tested material is full-length LL-37 rather than a fragment or analogue. A generic antimicrobial-peptide report is not an identity match.
For topical research, the vehicle and release characteristics are part of the preparation. A powder with a matching molecular name does not reproduce the clinical cream or solution.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Did the larger venous-ulcer trial succeed overall?
No. Its overall healing analysis did not show a significant benefit. The reported large-ulcer subgroup is exploratory, not equivalent to a positive primary result.
Does antibacterial activity prove it treats an infection?
No. Laboratory antimicrobial activity and patient outcomes differ. In the diabetic-foot study, the measured aerobic bacterial burden did not significantly decline.
Can topical study results support injections?
They do not establish injected exposure, effectiveness or safety. The route and formulation are central to the evidence.